

QUANTITY LIMIT CRITERIA FOR APPROVAL

1. ONE of the following:

a. The requested quantity (dose) does NOT exceed the program quantity limit

b. Information has been provided that fulfills the criteria listed under the "Allowed exception cases/diagnoses" (if applicable)

c. The requested quantity (dose) exceeds the program quantity limit AND ONE of the following:

i. BOTH of the following:

- 1. The requested agent does not have a maximum FDA labeled dose for the requested indication
- 2. Information has been provided to support therapy with a higher dose for the requested indication
- OR
- ii. BOTH of the following:
- 1. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication

2. Information has been provided to support why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity

limit

OR

iii. BOTH of the following:

- 1. The requested quantity (dose) exceeds the maximum FDA labeled dose for the requested indication
- 2. Information has been provided to support therapy with a higher dose for the requested indication

Length of Approval: up to 12 months

| Program | Target Agents Note: Brand and generic agents are subject to quantity limits | Dosage/Strength | Quantity Limit (Units/Day or as | Allowed exception cases/ diagnoses |
|---|---|--|---|------------------------------------|
| Accrufer PAQL | **Accrufer QL information is included in the individual program document | | | |
| Acute Migraine Agents PAQL | **Acute Migraine Agents QL information is included in the individual program docu | ument | | |
| ADHD PS | **ADHD QL information is included in the individual program document | | | |
| Afrezza PAQL | **Afrezza QL information is included in the individual program document | | | |
| Alinia QL | **Alinia QL information is included in the individual program document | | | |
| Amifampridine PAQL | **Amifampridine QL information is included in the individual program document | | | |
| Ampyra PAQL | **Ampyra QL information is included in the individual program document | | | |
| Androgens and Anabolic Steroids PAQL | **Androgen and Anabolic Steroids QL information is included in the individual prod | gram document | | |
| Anti-COVID19 Agents QL | **Anti-COVID19 Agents QL information is included in the individual program docu | iment | | |
| Antidepressants QL | **Antidepressants QL information is included in the individual program document | | | |
| Antiemetic Agents QL | **Antiemetic Agents QL information is included in the individual program documen | nt | | |
| Antifungal Agents (Brexafemme Cresemba Noxafil Vfend) PAOL | **Antifungal Agents (Brexafemme Cresemba Noxafil Vfend) QL information is incl | uded in the individual program document | | |
| Antifungal Agents (Ciclopirox, Efinaconazole, Itraconazole, Tavaborole, Terbinafine) PAQL | **Antifungal Agents (Ciclopirox, Efinaconazole, Itraconazole, Tavaborole, Terbinaf | fine) QL information is included in the individual progr | am document | |
| Anti-Influenza QL | **Anti-Influenza QL information is included in the individual program document | | | |
| Antiretroviral PS AR0722_r0123 | **Antiretroviral QL information is included in the individual program document | | | |
| ARB/Renin Inhibitors PS AR0722 | Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, Gen Angiotensin II Receptor Antagonists (ARBs), ARB Combinations Atacand (candesartan) Atacand (candesartan) Atacand (candesartan) Atacand HCT (candesartan/hydrochlorothiazide) Atacand HCT (candesartan/hydrochlorothiazide) Atacand HCT (candesartan/hydrochlorothiazide) Atacand HCT (candesartan/hydrochlorothiazide) Avapro (irbesartan) Avapro (irbesartan) Avapro (irbesartan) Avalide (irbesartan/hydrochlorothiazide) Avalide (irbesartan/hydrochlorothiazide) Azor (amlodipine/olmesartan medoxomil) | A mq tablets 8 mq tablets 16 mq tablets 32 mq tablets 16 mq/12.5 mq tablets 32 mq/12.5 mq tablets 32 mq/25 mq tablets 32 mq/25 mq tablets 30 mq tablets 150 mq tablets 150 mq/12.5 mq tablets 300 mq tablets 150 mq/12.5 mq tablets 150 mq/12.5 mq tablets | 2 tablets 2 tablets 2 tablets 1 tablet | |

5 mg/40 mg tablets

1 tablet

Azor (amlodipine/olmesartan medoxomil)

| And is designed concentration and account of the control of the co | | Azor (amlodipine/olmesartan medoxomil) Azor (amlodipine/olmesartan medoxomil) | 5 mg/40 mg tablets 10 mg/20 mg tablets | 1 tablet 1 tablet | |
|--|--------------------------------------|--|---|----------------------|--|
| Facility Owner O | | | | | |
| Demonst Citizenserian 100 mm 20 mms 1 20 mm 1 20 mms 1 2 | | | | | |
| Descript RT Otherwister March 100 | | | • | | |
| Denic of Color C | | · | | | |
| Berian MCT (names and Profession and Berian Control (Indian) C | | | | | |
| Court (Stortisch) Court (Stort | | | | | |
| Coase (Section 10 mg sables 1 abbet 1 | | Cozaar (losartan) | 25 mg tablets | 2 tablets | |
| Disease (Procedurals) | | | | | |
| Dispose Continued Dispose Continued Dispose Dispose Dispose Continued Dispose Continued Dispose Continued Dispose Continued Dispose Di | | | • | | |
| Dispose (Accidented Continued Cont | | | | | |
| Decom (canathan) | | | | | |
| Robert Form | | | • | | |
| Direct ICC (solica month/orden biomentance) Direct ICC (solica mon | | | • | | |
| December C. Content Procession Applications 1.00 months 1.00 m | | | | | |
| Description 1 1 1 1 1 1 1 1 1 | | | | | |
| Softe Applications | | | | | |
| Control (primerant) | | | | | |
| BelastryCont rails and Prichage 1 to plet 1 to p | | | | | |
| District (a mid of princy violant and in a control of mid of princy violant and in a control of mid of princy violant and in a control of mid of mi | | · | | | |
| Defined (ambidine) very description Section 1 1 1 1 1 1 1 1 1 1 | | Edarbyclor (azilsartan/chlorthalidone) | 40 mg/25 mg tablets | 1 tablet | |
| Ections (am colinity/elegation) Forting (am colinity) Fortin | | | | | |
| Enforce (amiconice)-yelestran () | | | | | |
| Edition Miller | | | | | |
| Extract H.C. Family in provided that physical parts any product of the parts of | | | | | |
| Future INCT (misotlosiny-kose-fed anti-futurins-interior 10 mm/s 60 mm/s 7.5 ms tablets 1 tablet | | | ** *** | | |
| Engine E | | | | | |
| Invasor (invasor Invitational Continue of the Continue of th | | | | | |
| Hyzar (fostran/hydrochrothiszide) 100 ms/12.5 ms tablets 1 tablet | | Exforge HCT (amlodipine/valsartan/hydrochlorothiazide) | 10 mg/320 mg/25 mg tablets | 1 tablet | |
| Invaar (invastran/invitroctiorottiisaide) 100 mm/25 min tablets 1 tablet | | | | | |
| Micardis (telinisartan) 40 mt abblets 1 tablet 4 tablet | | | | | |
| Micardis (reliminarian) Micardis (reliminarian) Micardis (reliminarian) Micardis (reliminarian) Micardis (reliminarian) Micardis (RT (reliminarian) Micardi | | | | | |
| Micardis MCI (refinestrant)/hydrochlorothazide) Micardis MCI (refinestrant)/hy | | · | · | | |
| Micardis HCI (felmisartan/fwiorchiorchisade) 40 mc/12.5 m tablets 1 tablet (felmisartan/fwiorchiorchiorchisade) 80 mc/12.5 m tablets 1 tablet (felmisartan/fwiorchiorchiorchisade) 1 felmiorchiorchiorchiorchiorchiorchiade 1 db mc/3 mc/2.5 m tablets 1 tablet (felmisartan/fwiorchiorchiorchisade) 1 felmiorchiorchiorchiorchiorchiorchiade 1 db mc/3 mc/2.5 mc tablets 1 tablet (felmisartan/fwiorchiorchiorchiade) 1 db mc/3 mc/2.5 mc tablets 1 tablet (felmisartan/fwiorchiorchiade) 1 db mc/3 mc/2.5 mc tablets 1 tablet (felmisartan/fwiorchiorchiade) 1 db mc/3 mc/2.5 mc tablets 1 tablet (felmisartan/fwiorchiorchiade) 1 db mc/3 mc/2.5 mc tablets 1 tablet (felmisartan/fwiorchiorchiade) 1 db mc/2.5 mc tablets 1 | | · | | | |
| Micardis HCT (relimisaran/hvdrochlorothisaide) Micardis HCT (relimisaran | | · | • | | |
| Tevete in ICT (earosatran/invidrochlorothiazide) 600 mm/12.5 ma tablets 1 tablet 1 t | | | | | |
| Tevetor HCT (eprosartan/hydrochlorothiazide) Tribenzor (olmesartan/moldoline/hydrochlorothiazide) Tribenzor (olmesartan/moldoline) Tribenzor (o | | | | 1 tablet | |
| Tribezzor (olmesartan/amlodipine/Mydrochlorothiazide) Tribezzor (olmesartan/amlodipine/Mydrochlorothia | | | | | |
| Tribenzor (olmesartan/amiddione/hydrochlorothiazide) Iribenzor (olmesartan/amiddione/ | | • | | | |
| Tribenzor (olmesartan/amlodipine/hydrochlorothiazide) 40 mg/15 mg/12.5 mg tablets 1 tablet 1 fribenzor (olmesartan/amlodipine/hydrochlorothiazide) 40 mg/10 mg/12.5 mg tablets 1 tablet 1 tablet 1 tribenzor (olmesartan/amlodipine/hydrochlorothiazide) 40 mg/10 mg/12.5 mg tablets 1 tablet 1 tablet 1 trynsta (telmisartan/amlodipine) 40 mg/10 mg/12.5 mg tablets 1 tablet 1 tab | | | | | |
| Tribenzor (olmesartan/amlodipine/hydrochlorothizaide) Iribenzor (olmesartan/amlodipine/hydrochlorothizaide) Iribenzor (olmesartan/amlodipine) Irvonsta (telmisartan/amlodipine) Ivvonsta (telmisartan/amlodipine) | | | | | |
| Tribenzor (olmesartan/amlodipine/hydrochlorothiazide) 40 md/10 md/15 md tablets 1 tablet Twynsta (telmisartan/amlodipine) 40 md/10 md tablets 1 tablet Twynsta (telmisartan/amlodipine) 40 md/10 md tablets 1 tablet Twynsta (telmisartan/amlodipine) 80 md/10 md tablets 1 tablet Twynsta (telmisartan/amlodipine) 10 md/12 md tablets 1 tablet Teltum (aliskiren) Teltum (aliskiren) Teltum (aliskiren) Teltum ma (taliskiren/hydrochlorothiazide) 10 md/12 5 md tablets 1 tablet Teltum ma HCT (aliskiren/hydrochlorothiazide) 10 md/12 5 md tablets 1 tablet Teltum ma HCT (aliskiren/hydrochlorothiazide) 10 md/12 5 md tablets 1 tablet Teltum ma HCT (aliskiren/hydrochlorothiazide) 10 md/12 5 md tablets 1 tablet Tribacce PAOL ***Alkayce QL information is included in the individual program document TR Amyloidosis PAOL ***Altra Amyloidosis OL information is included in the individual program document Try Amyloidosis PAOL ***Altra Amyloidosis OL information is included in the individual program document ***Altra Amyloidosis Catended Maintenance on the individual program document ***Altra Amyloidosis Catended Maintenance on the individual program document ***Bempedoic Acid QL information is included in the individual program document ***Bempedoic Acid QL information is included in the individual program document ***Bempedoic Acid QL information is included in the individual program document ***Bempedoic Acid QL information is included in the individual program document ***Bempedoic Acid QL information is included in the individual program document ***Bempedoic Acid QL information is included in the ind | | | | | |
| Twynsta (telnisartan/amlodipine) Twynsta (telmisartan/amlodipine) | | | | | |
| Twynsta (telmisartan/amlodignie) Twynsta (telmisartan/amlodignie) Twynsta (telmisartan/amlodignie) Yalsartan Reninthibitors, Renin Inhibitor Combinations Renin Inhibitors, Renin Inhibitor Combinations Tekturna (aliskiren) Tekturna HCT (aliskiren) Tekturna | | Twynsta (telmisartan/amlodipine) | | 1 tablet | |
| Twynsta (telmisartan/amlodipine) Velsartan Renin Inhibitors, Renin Inhibitor Combinations Renin Inhibitors, Renin Inhibitor Combinations Tektuma (aliskiren) Tektuma (aliskiren) Tektuma (aliskiren) Tektuma HCT (aliskiren/hydrochlorothiazide) T | | | | | |
| Valsartan Refin Inhibitors, Renin Inhibitor Combinations Tektuma (aliskiren) Tektuma (aliskiren) Tektuma (aliskiren) Tektuma (aliskiren) Tektuma (aliskiren) Tektuma HCT (alis | | | | | |
| Renin Inhibitors, Renin Inhibitor Combinations Fektuma (aliskiren) Fektuma (aliskiren) Fektuma (aliskiren) Fektuma (aliskiren) Fektuma (aliskiren) Fektuma (aliskiren) Fektuma HCT (aliskiren/hydrochlorothiazide) Fektuma HCT (aliskiren/hydrochl | | | | | |
| Tektuma (aliskiren) Tektuma HCT (aliskiren/hydrochlorothiazide) Te | | | 20 HIG/5 HIL SOIULION | OU IIIL | |
| Tekturna (aliskiren) Fekturna (TC (aliskiren/hydrochlorothiazide) Fekturna HCT (aliskiren/hydrochlorothiazide) Tekturna HCT (aliskiren/hydrochlorothiazide) | | - | 150 mg tablets | 1 tablet | |
| Tekturna HCT (aliskiren/hydrochlorothiazide) | | | • | | |
| rikayce PAOL **Arikayce QL information is included in the individual program document **Attra Amyloidosis PAQL **Attra Amyloidosis QL information is included in the individual program document **Attra Amyloidosis QL information is included in the individual program document **Attra Amyloidosis QL information is included in the individual program document **Attra Amyloidosis QL information is included in the individual program document **Attra Amyloidosis QL information is included in the individual program document **Attra Amyloidosis QL information is included in the individual program document **Attra Amyloidosis QL information is included in the individual program document **Attra Amyloidosis QL information is included in the individual program document **Attra Amyloidosis QL information is included in the individual program document **Attra Amyloidosis QL information is included in the individual program document **Baclofen QL information is included in the individual program document **Baclofen QL information is included in the individual program document **Bempedoic Acid PAQL **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid PAQL **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document | | • | · | | |
| Tekturna HCT (aliskiren/hydrochlorothiazide) 300 mg/25 mg tablets 1 tablet **Arikayce PAQL **Arikayce QL information is included in the individual program document **ATTR Amyloidosis PAQL **ATTR Amyloidosis QL information is included in the individual program document **Atypical Antipsychotics STQL **Atypical Antipsychotics QL information is included in the individual program document **Atypical Antipsychotics, Extended Maintenance gents AR0423 r0124 **Baclofen QL information is included in the individual program document **Baclofen QL information is included in the individual program document **Bempedoic Acid PAQL **Bempedoic Acid QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document | | | | | |
| **Arikayce QL information is included in the individual program document **ATTR Amyloidosis PAQL **ATTR Amyloidosis QL information is included in the individual program document **Attr Amyloidosis QL information is included in the individual program document **Attr Amyloidosis QL information is included in the individual program document **Atypical Antipsychotics, Extended Maintenance **Atypical Antipsychotics Extended Maintenance QL information is included in the individual program document **Atypical Antipsychotics Extended Maintenance QL information is included in the individual program document **Baclofen QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document | | | | | |
| **ATTR Amyloidosis PAQL **ATTR Amyloidosis QL information is included in the individual program document **Atypical Antipsychotics STQL **Atypical Antipsychotics QL information is included in the individual program document **Atypical Antipsychotics, Extended Maintenance gents AR0423 r0124 **Baclofen QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document | | Tekturna HCT (aliskiren/hydrochlorothiazide) | 300 mg/25 mg tablets | 1 tablet | |
| **ATTR Amyloidosis PAQL **ATTR Amyloidosis QL information is included in the individual program document **Atypical Antipsychotics STQL **Atypical Antipsychotics QL information is included in the individual program document **Atypical Antipsychotics, Extended Maintenance gents AR0423 r0124 **Baclofen QL information is included in the individual program document **Baclofen QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document | rikavce PAOI | **Arikayce OL information is included in the individual program document | | | |
| **Atypical Antipsychotics, Extended Maintenance gents AR0423 r0124 **Baclofen QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **BPH QL information is included in the individual program document | | | cument | | |
| **Atypical Antipsychotics, Extended Maintenance parts AR0423 r0124 **Baclofen QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document | | | | | |
| **Baclofen QL information is included in the individual program document **Bempedoic Acid PAQL **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **BPH QL information is included in the individual program document **BPH QL information is included in the individual program document | typical Antipsychotics STQL | **Atypical Antipsychotics QL information is included in the individual progra | in document | | |
| **Bempedoic Acid QL information is included in the individual program document **Bempedoic Acid QL information is included in the individual program document **BPH QL information is included in the individual program document **R0722 r1022 | | **Atypical Antipsychotics Extended Maintenance QL information is included in the individual program document | | | |
| enign Prostatic Hypertrophy (BPH) PS **BPH QL information is included in the individual program document R0722 r1022 | | | | | |
| R0722 r1022 | gents AR0423 r0124 | **Baclofen QL information is included in the individual program document | | | |
| AR0722 r1022 | gents AR0423 r0124 aclofen PAQL | | ıment | | |
| iologic Immunomodulators PAQL **Biologic Immunomodulators QL information is included in the individual program document | aclofen PAQL empedoic Acid PAQL | **Bempedoic Acid QL information is included in the individual program docu | ıment | | |
| | enign Prostatic Hypertrophy (BPH) PS | **Bempedoic Acid QL information is included in the individual program docu | ıment | | |

| Bisphosphonates QL | **Bisphosphonates QL information is included in the individual program document |
|---|---|
| Bonjesta Diclegis PAQL | **Bonjesta Diclegis QL information is included in the individual program document |
| Buprenorphine, buprenorphine-naloxone QL | **Buprenorphine, buprenorphine-naloxone QL information is included in the individual program document |
| Cablivi PAQL | **Cablivi QL information is included in the individual program document |
| Camzyos PAQL | **Camzyos QL information is included in the individual program document |
| CFTR PAQL | **CFTR QL information is included in the individual program document |
| CGRP PAQL | **CGRP QL information is included in the individual program document |
| Cibingo PAQL | **Cibingo QL information is included in the individual program document |
| CMV QL | **CMV QL information is included in the individual program document |
| Coagulation Factor VIIa PAQL | **Coagulation Factor VIIa QL information is included in the individual program document |
| Combination NSAID PAQL | **Combination NSAID QL information is included in the individual program document |
| Constipation Agents PAQL | **Constipation Agents QL information is included in the individual program document |
| DPP-4 Inhibitors STQL | **DPP-4 Inhibitors QL information is included in the individual program document |
| ED Agents PAQL | **ED Agents QL information is included in the individual program document |
| Egrifta PAQL | **Egrifta QL information is included in the individual program document |
| Elagolix/Relugolix PAQL | **Elagolix QL information is included in the individual program document |
| Emflaza PAQL | **Emflaza QL information is included in the individual program document |
| Empaveli PAQL | **Empaveli QL information is included in the individual program document |
| Enspryng PAQL | **Enspryng QL information is included in the individual program document |
| Evrysdi PAQL | **Evrysdi QL information is included in the individual program document |
| Eysuvis PAQL | **Eysuvis QL information is included in the individual program document |
| Lysuvis PAQL | Lysuvis QL initormation is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document |
| | |
| Factor VIII and von Willebrand Factor PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Galafold QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Galafold QL information is included in the individual program document **GLP-1 QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Galafold QL information is included in the individual program document **GLP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Galafold QL information is included in the individual program document **GLP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **Gonadotropin Hormones QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL HCN Channel Blocker PAQL Hemlibra PAQL Hemophilia Factor IX PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Galafold QL information is included in the individual program document **GLP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **Gonadotropin Hormones QL information is included in the individual program document **HCN Channel Blocker QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL HCN Channel Blocker PAQL Hemlibra PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Galafold QL information is included in the individual program document **GLP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **Gonadotropin Hormones QL information is included in the individual program document **HCN Channel Blocker QL information is included in the individual program document **Hemlibra QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL HCN Channel Blocker PAQL Hemlibra PAQL Hemophilia Factor IX PAQL Hepatitis C Direct Acting Antivirals PAQL Hereditary Angioedema PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Galafold QL information is included in the individual program document **GLP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **Gonadotropin Hormones QL information is included in the individual program document **HCN Channel Blocker QL information is included in the individual program document **Hempihilia Factor IX QL information is included in the individual program document **Hempophilia Factor IX QL information is included in the individual program document **Hepatitis C Direct Acting Antivirals QL information is included in the individual program document **Hereditary Angioedema QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL HCN Channel Blocker PAQL Hemlibra PAQL Hemophilia Factor IX PAQL Hepatitis C Direct Acting Antivirals PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Galafold QL information is included in the individual program document **GLP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **Gonadotropin Hormones QL information is included in the individual program document **HCN Channel Blocker QL information is included in the individual program document **Hemlibra QL information is included in the individual program document **Hemophilia Factor IX QL information is included in the individual program document **Hepatitis C Direct Acting Antivirals QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL HCN Channel Blocker PAQL Hemlibra PAQL Hemophilia Factor IX PAQL Hepatitis C Direct Acting Antivirals PAQL Hereditary Angioedema PAQL Hetlioz PAQL HoFH PAQL | **Fractor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Galafold QL information is included in the individual program document **GLP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **Gonadotropin Hormones QL information is included in the individual program document **HCN Channel Blocker QL information is included in the individual program document **Hempibra QL information is included in the individual program document **Hempophilia Factor IX QL information is included in the individual program document **Hepatitis C Direct Acting Antivirals QL information is included in the individual program document **Hereditary Angioedema QL information is included in the individual program document **Hereditary Angioedema QL information is included in the individual program document **Hereditary Information is included in the individual program document **Hereditary Information is included in the individual program document **Horth QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL HCN Channel Blocker PAQL Hemlibra PAQL Hemophilia Factor IX PAQL Hepatitis C Direct Acting Antivirals PAQL Hereditary Angioedema PAQL Hetlioz PAQL HoFH PAQL HSDD PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **GLP-1 QL information is included in the individual program document **GLP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **Gonatorion Hormones QL information is included in the individual program document **HCN Channel Blocker QL information is included in the individual program document **Hempilipra QL information is included in the individual program document **Hempophilia Factor IX QL information is included in the individual program document **Hepatitis C Direct Acting Antivirals QL information is included in the individual program document **Hereditary Angioedema QL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Information is included in the individual program document **HoFH OL information is included in the individual program document **HoFH OL information is included in the individual program document **HoFH OL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL HCN Channel Blocker PAQL Hemlibra PAQL Hemophilia Factor IX PAQL Hepatitis C Direct Acting Antivirals PAQL Hereditary Angioedema PAQL Hetlioz PAQL HoFH PAQL HSDD PAQL Hyperhidrosis PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Fintepla QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Galafold QL information is included in the individual program document **GIP-1 QL information is included in the individual program document **Glocose Test Strips/Meters QL information is included in the individual program document **Gonadotropin Hormones QL information is included in the individual program document **HCN Channel Blocker QL information is included in the individual program document **Hempilbra QL information is included in the individual program document **Hempilbra QL information is included in the individual program document **Hempilbra CD Information is included in the individual program document **Hempilbra CD Information is included in the individual program document **Hereditary Angloedema QL information is included in the individual program document **Hereditary Angloedema QL information is included in the individual program document **Herbitoz QL information is included in the individual program document **HoFH QL information is included in the individual program document **Herbitoz QL information is included in the individual program document **Herbitoz QL information is included in the individual program document **Herbitoz QL information is included in the individual program document **Herbitoz QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL HCN Channel Blocker PAQL Hemlibra PAQL Hemophilia Factor IX PAQL Hepatitis C Direct Acting Antivirals PAQL Hereditary Angioedema PAQL Hetlioz PAQL HoFH PAQL HSDD PAQL Hyperhidrosis PAQL Imcivree PAQL | **Factor VIII and von Willebrand Factor OL information is included in the individual program document **Fintepia QL information is included in the individual program document **Galafold OL information is included in the individual program document **Galafold OL information is included in the individual program document **GIP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **Gonadotropin Hormones QL information is included in the individual program document **HCN Channel Blocker QL information is included in the individual program document **Hempilita QL information is included in the individual program document **Hempilita Factor IX QL information is included in the individual program document **Hereditary Angioedema QL information is included in the individual program document **Hereditary Angioedema QL information is included in the individual program document **Hereditary Angioedema QL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **HoFH QL information is included in the individual program document **HoFH QL information is included in the individual program document **Hyperhidrosis QL information is included in the individual program document **Hiperhidrosis QL information is included in the individual program document **Hiperhidrosis QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL HCN Channel Blocker PAQL Hemlibra PAQL Hemophilia Factor IX PAQL Hepatitis C Direct Acting Antivirals PAQL Hereditary Angioedema PAQL Hetlioz PAQL HoFH PAQL Hyperhidrosis PAQL Imcivree PAQL Inhaled Antibiotics Duplicate Therapy PAQL | **Factor VIII and von Willebrand Factor QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Gabapentin ER QL information is included in the individual program document **Gal2-1 QL information is included in the individual program document **GLP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **HOL Channel Blocker QL information is included in the individual program document **Hemphilibra QL information is included in the individual program document **Hemphilibra Tester IX QL information is included in the individual program document **Hemphilibra C Direct Acting Antivirals QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document **Hereditary Anoicedema QL information is included in the individual program document |
| Factor VIII and von Willebrand Factor PAQL Fintepla PAQL Gabapentin ER STQL Galafold PAQL GLP-1 Agonists PAQL Glucose Test Strips/Meters QL Gonadotropin Hormones PAQL HCN Channel Blocker PAQL Hemlibra PAQL Hemophilia Factor IX PAQL Hepatitis C Direct Acting Antivirals PAQL Hereditary Angioedema PAQL Hetlioz PAQL HoFH PAQL HSDD PAQL Hyperhidrosis PAQL Imcivree PAQL | **Factor VIII and von Willebrand Factor OL information is included in the individual program document **Fintepia QL information is included in the individual program document **Galafold OL information is included in the individual program document **Galafold OL information is included in the individual program document **GIP-1 QL information is included in the individual program document **Glucose Test Strips/Meters QL information is included in the individual program document **Gonadotropin Hormones QL information is included in the individual program document **HCN Channel Blocker QL information is included in the individual program document **Hempilita QL information is included in the individual program document **Hempilita Factor IX QL information is included in the individual program document **Hereditary Angioedema QL information is included in the individual program document **Hereditary Angioedema QL information is included in the individual program document **Hereditary Angioedema QL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document **Hereditary Angioedema OL information is included in the individual program document |

| Insulin Pumps QL | **Insulin Pumps QL information is included in the individual program document |
|--|--|
| Interleukin (IL)-13 Antagonists PAQL | **Interleukin-13 Antagonists QL information is included in the individual program document |
| Interleukin (IL)-1 Inhibitors PAQL | **Interleukin-1 Inhibitors QL information is included in the individual program document |
| Interleukin (IL)-4 Inhibitors PAQL | **Interleukin-4 Inhibitors QL information is included in the individual program document |
| Interleukin (IL)-5 Inhibitors PAQL | **Interleukin-5 Inhibitors QL information is included in the individual program document |
| Interstitial Lung Disease PAQL | **Interstitial Lung Disease QL information is included in the individual program document |
| Iron Chelation PAQL | **Iron Chelation QL information is included in the individual program document |
| Isturisa PAQL | **Isturisa QL information is included in the individual program document |
| Ivermectin QL | **Ivermectin QL information is included in the individual program document |
| Jynarque PAQL | **Jynarque QL information is included in the individual program document |
| Kerendia PAQL | **Kerendia QL information is included in the individual program document |
| Ketorolac QL | **Ketorolac QL information is included in the individual program document |
| Keveyis PAQL | **Keveyis QL information is included in the individual program document |
| Korlym PAQL | **Korlym QL information is included in the individual program document |
| Long Acting Insulin | **Long Acting Insulin QL information is included in the individual program document |
| Low Molecular Weight Heparins (LMWH) and Arixtra | **Low Molecular Weight Heparins (LMWH) and Arixtra QL information is included in the individual program document |
| Lucemyra PAQL | **Lucemyra QL information is included in the individual program document |
| Lupus PAQL | **Lupus QL information is included in the individual program document |
| Lyrica and Savella STQ | **Lyrica and Savella QL information is included in the individual program document |
| Metformin ER STQL | **Metformin ER QL information is included in the individual program document |
| Multiple Sclerosis PAQL | **Multiple Sclerosis QL information is included in the individual program document |
| Nasal Antiepileptics QL | **Nasal antiepileptics QL information is included in the individual program document |
| Nasal Inhalers QL | **Nasal inhalers QL information is included in the individual program document |
| Natpara PAQL | **Natpara QL information is included in the individual program document |
| Neurotrophic Keratitis PAQL | **Neurotrophic Keratitis QL information is included in the individual program document |
| Nocturia PAQL | **Nocturia QL information is included in the individual program document |
| Northera PAQL | **Northera QL information is included in the individual program document |
| Ocaliva PAQL | **Ocaliva QL information is included in the individual program document |
| Ophthalmic Immunomodulators PAQL | **Ophthalmic Immunomodulators QL information is included in the individual program document |
| Ophthalmic Prostaglandins PS AR0722 | **Ophthalmic Prostaglandins QL information is included in the individual program document |
| Opioids ER PAQL | **Opioids ER QL information is included in the individual program document |
| Opioids IR NTT with QL | **Opioids IR QL information is included in the individual program document |
| Opzelura PAQL | **Opzelura QL information is included in the individual program document |
| Oral Anticoagulant Agents QL PAQL | **Oral Anticoagulant Agents QL information is included in the individual program document |
| Oral Immunotherapy PAQL | **Oral Immunotherapy QL information is included in the individual program document |
| Oral Inhalers QL | **Oral Inhalers QL information is included in the individual program document |
| Oral PAH Agents PAQL | **Oral PAH Agents QL information is included in the individual program document |
| Otezla PAQL | **Otezla QL information is included in the individual program document |
| Oxbryta PAQL | **Oxbryta QL information is included in the individual program document |
| Oxybate PAQL | **Oxybate QL information is included in the individual program document |

| Pain Medications QL | **Pain Medications QL information is included in the individual program document | | | |
|---|--|--|---|---|
| Parathyroid Hormone Analogs for Osteoporos PAOL | ** Parathyroid Hormone Analogs for Osteoporosis QL information is included in the individual program document | | | |
| PCSK-9 Inhibitors PAQL | **PCSK-9 Inhibitors QL information is included in the individual program document | | | |
| Peanut Allergy PAQL | **Peanut Allergy QL information is included in the individual program document | | | |
| PPIs PS AR0723 r0324 | Quantity limit applies to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Ope Aciphex (rabeprazole) Aciphex Sprinkle (rabeprazole) Esomeprazole strontium Dexilant (dexlansoprazole) Dexilant (dexlansoprazole) Nexium (esomeprazole) Prevacid (lansoprazole) Protonix (pantoprazole) Prilosec (omeprazole) Prilosec (omeprazole) Protonix (pantoprazole) Protonix (pantoprazole) Protonix (pantoprazole) Protonix (pantoprazole) Protonix (pantoprazole) Yoquezna (vonoprazan) Zeqerid (omeprazole/sodium bicarbonate) Zegerid (omeprazole/sodium bicarbonate) Zegerid (omeprazole/sodium bicarbonate) Zegerid (omeprazole/sodium bicarbonate) | n, Health Insurance Marketplace, and KeyRx. 20 mg delayed-release tablets 5 mg capsule sprinkle 10 mg capsule sprinkle 49.3 mg capsule 30 mg delayed-release capsules 60 mg delayed-release capsules 40mg/20ml suspension 20 mg delayed-release capsules 40 mg delayed-release capsules 10 mg delayed-release oral suspension 20 mg delayed-release oral suspension 20 mg delayed-release oral suspension 20 mg delayed-release oral suspension 2.5 mg susp pack 5 mg susp pack 15 mg delayed-release capsules 30 mg delayed-release capsules 15 mg oral suspension (packets) 30 mg oral suspension (packets) 15 mg delayed-release orally disintegrating tablet 30 mg delayed-release capsules 20 mg delayed-release capsules 20 mg delayed-release capsules 20 mg delayed-release capsules 20 mg oral suspension (packets) 10 mg oral suspension (packets) 10 mg oral suspension (packets) 20 mg delayed-release tablets 40 mg delayed-release capsules 20 mg immediate-release capsules 20 mg immediate-release capsules 20 mg powder for oral suspension (packets) | 1 capsule 1 capsule 1 capsule 1 capsule 2 packets 1 packet 1 packet 1 tablet 1 tablet 1 tablet 1 tablet 1 capsule 1 capsule 1 capsule 1 capsule | 1. Hypersecretory disease (i.e., Zollinger-Ellison Syndrome), Barrett's esophagitis, or esophageal stricture - approve 12 months OR 2. Conventional therapy failure (failure of standard labeled dosing with the requested agent) - approve 12 months OR 3. H pylori treatment - approve once |
| Pseudobulbar Affect PAQL | **Pseudobulbar Affect QL information is included in the individual program document | | | |
| Pyrukynd PAQL | **Pyrukynd QL information is included in the individual program document | | | |
| Radicava PAQL | **Radicava QL information is included in the individual program document | | | |
| Rapid to Intermediate Acting Insulin | **Rapid to Intermediate Acting Insulin QL information is included in the individual program | n document | | |
| Recorlev PAQL | **Recorlev QL information is included in the individual program document | | | |
| Rho Kinase Inhibitor | **Rho Kinase Inhibitor QL information is included in the individual program document | | | |
| SA Oncology PAQL | **SA Oncology QL information is included in the individual program document | | | |
| Samsca PAQL | **Samsca QL information is included in the individual program document | | | |
| SGLT Inhibitors STQL | **SGLT Inhibitors QL information is included in the individual program document | | | |
| Somatostatin Analogs PAQL | **Somatostatin Analogs QL information is included in the individual program document | | | |
| SSIA PAQL | **SSIA QL information is included in the individual program document | | | |
| Statins PS AR0723_r1123 | Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Oper Altoprev (lovastatin extended release) Altoprev (lovastatin extended release) Altoprev (lovastatin extended release) Atorvaliq (atorvastatin) Crestor (rosuvastatin) Crestor (rosuvastatin) Crestor (rosuvastatin) | n, Health Insurance Marketplace, and KeyRx. 20 mg tablets 40 mg tablets 60 mg tablets 20mg/5ml suspension 5 mg tablets 10 mg tablets 20 mg tablets | 1 tablet 1 tablet 1 tablet 20ml 1½ tablets 1½ tablets 1½ tablets | |

40 mg tablets

5 mg capsules

10 mg capsules 20 mg capsules 1 tablet

1 capsule

2 capsule 3 capsule

Crestor (rosuvastatin)

Ezallor Sprinkle (rosuvastatin)

Ezallor Sprinkle (rosuvastatin) Ezallor Sprinkle (rosuvastatin)

| | Ezallor Sprinkle (rosuvastatin) | 20 mg capsules | 3 capsule |
|---|---|---|---|
| | Ezallor Sprinkle (rosuvastatin) ezetimibe/atorvastatin | 40 mg capsules 10-10mg | 4 capsule 1 tablet |
| | ezetimibe/atorvastatin | 10-20mg | 1 tablet |
| | ezetimibe/atorvastatin | 10-40mg | 1 tablet |
| | ezetimibe/atorvastatin | 10-80mg | 1 tablet |
| | Flolipid (simvastatin oral suspension) | 20 mg/5 mL suspension | 5 mLs |
| | Flolipid (simvastatin oral suspension) | 40 mg/5 mL suspension | 10 mLs |
| | fluvastatin | 20 mg capsules | 2 capsules |
| | fluvastatin | 40 mg capsules | 2 capsules |
| | Lescol XL (fluvastatin extended release) | 80 mg tablets | 1 tablet |
| | Lipitor (atorvastatin) | 10 mg tablets | 1½ tablets |
| | Lipitor (atorvastatin) | 20 mg tablets | 1½ tablets |
| | Lipitor (atorvastatin) | 40 mg tablets | 1½ tablets |
| | Lipitor (atorvastatin) | 80 mg tablets | 1 tablet |
| | Livalo (pitavastatin) | 1 mg tablets | 1½ tablets |
| | Livalo (pitavastatin) | 2 mg tablets | 1½ tablets |
| | Livalo (pitavastatin) | 4 mg tablets | 1 tablet |
| | lovastatin | 10 mg tablets | 2 tablets |
| | lovastatin | 20 mg tablets | 2 tablets |
| | lovastatin | 40 mg tablets 10 mg tablets | 2 tablets |
| | pravastatin Pravachol (pravastatin) | 20 mg tablets | 1½ tablets 1½ tablets |
| | Pravachol (pravastatin) Pravachol (pravastatin) | 40 mg tablets | 1½ tablets |
| | pravastatin | 80 mg tablets | 1 tablet |
| | Roszet (exetimibe/rosuvastatin) | 5 mg/10 mg tablet | 1 tablet |
| | Roszet (exetimibe/rosuvastatin) Roszet (exetimibe/rosuvastatin) | 10 mg/10 mg tablet | 1 tablet |
| | Roszet (exetimibe/rosuvastatin) Roszet (exetimibe/rosuvastatin) | 20 mg/10 mg tablet | 1 tablet |
| | Roszet (exetimibe/rosuvastatin) Roszet (exetimibe/rosuvastatin) | 40 mg/10 mg tablet | 1 tablet |
| | Vytorin (ezetimibe/simvastatin) | 10 mg/ 10 mg tablets | 1 tablet |
| | Vytorin (ezetimbe/simvastatin) Vytorin (ezetimibe/simvastatin) | 10 mg/ 20 mg tablets | 1 tablet |
| | Vytorin (ezetimibe/simvastatin) Vytorin (ezetimibe/simvastatin) | 10 mg/ 40 mg tablets | 1 tablet |
| | Vytorin (ezetimibe/simvastatin) Vytorin (ezetimibe/simvastatin) | 10 mg/ 80 mg tablets | 1 tablet |
| | simvastatin | 5 mg tablets | 1½ tablets |
| | Zocor (simvastatin) | 10 mg tablets | 1½ tablets |
| | Zocor (simvastatin) | 20 mg tablets | 2 tablets |
| | Zocor (simvastatin) | 40 mg tablets | 1½ tablets |
| | Zocor (simvastatin) | 80 mg tablets | 1 tablet |
| | Zypitamag (pitavastatin) | 1 mg | 1½ tablets |
| | Lypitainag (pitavastatin) | ± 1119 | 172 (45)(45) |
| | Zypitamag (pitayastatin) | 2 ma | 1½ tablets |
| | Zypitamag (pitavastatin) Zypitamag (pitavastatin) | 2 mg 4 mg | 1½ tablets 1 tablets |
| | Zypitamag (pitavastatin) Zypitamag (pitavastatin) | 2 mg 4 mg | 1½ tablets 1 tablets |
| Substrate Reduction Therapy PAQL | | 4 mg | |
| Substrate Reduction Therapy PAQL | Zypitamag (pitavastatin) | 4 mg | |
| Substrate Reduction Therapy PAQL Sucraid PAQL | Zypitamag (pitavastatin) | 4 mg | |
| Sucraid PAQL | **Substrate Reduction Therapy QL information is included in the individual program docum **Sucraid QL information is included in the individual program document | 4 mg | |
| | Zypitamag (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program docum | 4 mg | |
| Sucraid PAQL Sucralfate Suspension PAQL | **Substrate Reduction Therapy QL information is included in the individual program docum **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document | 4 mg | |
| Sucraid PAQL | **Substrate Reduction Therapy QL information is included in the individual program docum **Sucraid QL information is included in the individual program document | 4 mg | |
| Sucraid PAQL Sucralfate Suspension PAQL | **Substrate Reduction Therapy QL information is included in the individual program docum **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document | 4 mg | |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL | Zypitamag (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document | 4 mg | |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL | Zypitamag (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document | 4 mg | |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL | **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document | 4 mg | |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL | Zypitamag (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document | 4 mg | |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL | **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document | 4 mg | |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL | **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document | 4 mg | |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL | **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document | 4 mg ent ocument | 1 tablets |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, | **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document | 4 mg ent ocument | 1 tablets |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL | **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document | 4 mg ent ocument | 1 tablets |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | **Substrate Reduction Therapy QL information is included in the individual program docume **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information | ent ocument is included in the individual program document | 1 tablets |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, | **Substrate Reduction Therapy QL information is included in the individual program docume **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, | ocument is included in the individual program document Health Insurance Marketplace, and KeyRx. | 1 tablets ent |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamag (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) | ent ocument is included in the individual program document Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) | 1 tablets 1 tablets 1 tablets 1 tablets |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | **Substrate Reduction Therapy QL information is included in the individual program docume **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, | ocument is included in the individual program document Health Insurance Marketplace, and KeyRx. | 1 tablets ent |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | **Substrate Reduction Therapy QL information is included in the individual program docume **Sucraid QL information is included in the individual program document **Sucraifate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Aclovate (alclometasone dipropionate) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) | 1 tablets ent 120 grams/30 days 120 grams/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamaq (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) | 1 tablets ent 120 qrams/30 days 120 grams/30 days 120 grams/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamaq (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program docume **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) | 1 tablets ent 120 qrams/30 days 120 grams/30 days 120 grams/30 days 120 grams/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | **Substrate Reduction Therapy QL information is included in the individual program docume **Sucraid QL information is included in the individual program document **Sucraifate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 gm, 45 gm, 60 gm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 gm) | 1 tablets ent 120 grams/30 days 120 grams/30 days 120 grams/30 days 120 grams/30 days 118.4 mL/30 days 120 grams/30 days 120 grams/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | **Substrate Reduction Therapy QL information is included in the individual program docume **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) Bryhali (halobetasol propionate) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 qm) 0.01% lotion (60 qm, 100 qm) | 1 tablets ent 120 qrams/30 days 120 grams/30 days 120 grams/30 days 120 grams/30 days 120 qrams/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamaq (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tarneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) Bryhali (halobetasol propionate) Capex (fluocinolone acetonide) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 qm) 0.01% lotion (60 qm, 100 qm) 0.01% shampoo (120 mL) | 1 tablets ent 120 qrams/30 days 120 grams/30 days 120 grams/30 days 118.4 mL/30 days 120 qrams/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamaq (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) Bryhali (halobetasol propionate) Capex (fluocinolone acetonide) Clobex (clobetasol propionate) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 qm) 0.01% lotion (60 qm, 100 qm) 0.01% shampoo (120 mL) 0.05% spray (59 mL, 125 mL) | 1 tablets ent 120 qrams/30 days 120 grams/30 days 120 grams/30 days 120 qrams/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamaq (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) Bryhali (halobetasol propionate) Capex (fluocinolone acetonide) Clobex (clobetasol propionate) Clobex (clobetasol propionate) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 qm) 0.01% lotion (60 qm, 100 qm) 0.01% shampoo (120 mL) 0.05% spray (59 mL, 125 mL) 0.05% lotion (59 mL, 118 mL) | 1 tablets ent 120 qrams/30 days 120 grams/30 days 120 grams/30 days 118.4 mL/30 days 120 qrams/30 days 120 qrams/30 days 120 qrams/30 days 200 qrams/30 days 200 qrams/30 days 200 qrams/30 days 840 mL/28 days 840 mL/28 days 177 mL/28 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamaq (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) Bryhali (halobetasol propionate) Capex (fluocinolone acetonide) Clobex (clobetasol propionate) Clobex (clobetasol propionate) Clobex (clobetasol propionate) Clobex (clobetasol propionate) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 qm) 0.01% lotion (60 qm, 100 qm) 0.01% shampoo (120 mL) 0.05% spray (59 mL, 125 mL) 0.05% lotion (59 mL, 118 mL) 0.05% shampoo (118 mL) | 1 tablets 20 qrams/30 days 120 grams/30 days 120 grams/30 days 118.4 mL/30 days 120 qrams/30 days 200 qrams/30 days 206 mL/28 days 236 mL/28 days 236 mL/28 days 236 mL/28 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamag (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tarneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) Bryhali (halobetasol propionate) Clobex (clobetasol propionate) Cloderm (clocortolone pivalate) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 qm) 0.01% lotion (60 qm, 100 qm) 0.01% shampoo (120 mL) 0.05% spray (59 mL, 125 mL) 0.05% lotion (59 mL, 118 mL) 0.05% shampoo (118 mL) 0.05% shampoo (118 mL) 0.1% cream (45 qm, 75 qm, 90 qm) | 1 tablets 20 qrams/30 days 120 grams/30 days 120 grams/30 days 118.4 mL/30 days 120 qrams/30 days 840 mL/28 days 236 mL/28 days 177 mL/28 days 120 qrams/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamaq (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucraifate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) Bryhali (halobetasol propionate) Capex (fluocinolone acetonide) Clobex (clobetasol propionate) Clobex (clobetasol propionate) Clobex (clobetasol propionate) Clobex (clobetasol propionate) Cloderm (clocortolone pivalate) Cordran (flurandrenolide) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 qm) 0.01% lotion (60 qm, 100 qm) 0.01% shampoo (120 mL) 0.05% spray (59 mL, 125 mL) 0.05% spray (59 mL, 125 mL) 0.05% shampoo (118 mL) 0.05% shampoo (118 mL) 0.1% cream (45 qm, 75 qm, 90 qm) 4 mcq/cm2 (80 in x 3 in) | 1 tablets 20 qrams/30 days 120 grams/30 days 120 grams/30 days 120 qrams/30 days 20 qrams/30 days 120 qrams/30 days 120 qrams/30 days 120 qrams/30 days 200 qrams/30 days 200 qrams/30 days 200 qrams/30 days 840 mL/28 days 236 mL/28 days 177 mL/28 days 120 qrams/30 days 1 box/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamaq (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) Bryhali (halobetasol propionate) Clobex (clobetasol propionate) Cloderm (clocortolone pivalate) Cordran (flurandrenolide) Cordran (flurandrenolide) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 qm) 0.01% lotion (60 qm, 100 qm) 0.01% shampoo (120 mL) 0.05% spray (59 mL, 125 mL) 0.05% spray (59 mL, 118 mL) 0.05% shampoo (118 mL) 0.05% shampoo (118 mL) 0.1% cream (45 qm, 75 qm, 90 qm) 4 mcq/cm2 (80 in x 3 in) 0.025% cream (120 qm) | 1 tablets 20 qrams/30 days 120 grams/30 days 120 grams/30 days 120 qrams/30 days 200 qrams/30 days 210 qrams/30 days 236 mL/28 days 236 mL/28 days 177 mL/28 days 120 qrams/30 days 120 qrams/30 days 120 qrams/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamaq (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucraifate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tavneos QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) Bryhali (halobetasol propionate) Capex (fluocinolone acetonide) Clobex (clobetasol propionate) Clobex (clobetasol propionate) Clobex (clobetasol propionate) Clobex (clobetasol propionate) Cloderm (clocortolone pivalate) Cordran (flurandrenolide) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 qm) 0.01% lotion (60 qm, 100 qm) 0.01% shampoo (120 mL) 0.05% spray (59 mL, 125 mL) 0.05% spray (59 mL, 118 mL) 0.05% shampoo (118 mL) 0.05% shampoo (118 mL) 0.1% cream (45 qm, 75 qm, 90 qm) 4 mcq/cm2 (80 in x 3 in) | 1 tablets 20 qrams/30 days 120 grams/30 days 120 grams/30 days 120 qrams/30 days 20 qrams/30 days 120 qrams/30 days 120 qrams/30 days 120 qrams/30 days 200 qrams/30 days 200 qrams/30 days 200 qrams/30 days 840 mL/28 days 236 mL/28 days 177 mL/28 days 120 qrams/30 days 1 box/30 days |
| Sucraid PAQL Sucralfate Suspension PAQL Sunosi PAQL Tarpeyo PAQL Tavneos PAQL Thrombopoietin Receptor Agonists PAQL TIRF PAQL Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents PAQL | Zypitamaq (pitavastatin) **Substrate Reduction Therapy QL information is included in the individual program document **Sucraid QL information is included in the individual program document **Sucralfate Suspension QL information is included in the individual program document **Sunosi QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Tarpeyo QL information is included in the individual program document **Thrombopoietin Receptor Agonists QL information is included in the individual program document **TIRF QL information is included in the individual program document **Topical Actinic Keratosis, Basal Cell Carcinoma, and Genital Warts Agents QL information Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Aclovate (alclometasone dipropionate) Ala Scalp (hydrocortisone) ApexiCon E (diflorasone diacetate) Aristocort HP (triamcinolone acetonide) Bryhali (halobetasol propionate) Clobex (clobetasol propionate) Cloderm (clocortolone pivalate) Cordran (flurandrenolide) Cordran (flurandrenolide) | ent ocument is included in the individual program docume Health Insurance Marketplace, and KeyRx. 0.05% cream (15 qm, 45 qm, 60 qm) 0.05% ointment (15 gm, 45 gm, 60 gm) 2% lotion (29.6 mL, 59.2 mL) 0.05% emollient cream (30 mq, 60 qm) 0.5% ointment (15 qm) 0.01% lotion (60 qm, 100 qm) 0.01% shampoo (120 mL) 0.05% spray (59 mL, 125 mL) 0.05% spray (59 mL, 118 mL) 0.05% shampoo (118 mL) 0.05% shampoo (118 mL) 0.1% cream (45 qm, 75 qm, 90 qm) 4 mcq/cm2 (80 in x 3 in) 0.025% cream (120 qm) | 1 tablets 20 qrams/30 days 120 grams/30 days 120 grams/30 days 120 qrams/30 days 200 qrams/30 days 210 qrams/30 days 236 mL/28 days 236 mL/28 days 177 mL/28 days 120 qrams/30 days 120 qrams/30 days 120 qrams/30 days |

| Cordran (flurandrenolide) | 0.05% lotion (120 mL) | 120 mL/30 days |
|---|--|-------------------------------------|
| Cordran (flurandrenolide) | 0.05% iotion (120 mz) | 120 me/30 days |
| | | |
| Cutivate (fluticasone propionate) | 0.05% lotion (60 mL, 120 mL) | 120 mL/30 days |
| Cutivate (fluticasone propionate) | 0.05% cream (15 gm, 30 gm, 60 gm) | 120 grams/30 days |
| Cutivate (fluticasone propionate) | 0.005% ointment (15 gm, 30 gm, 60 gm) | 120 grams/30 days |
| Cycle cout (and sin anida) | 0.10/ 2022 20 (15 202 20 202 60 202) | 120 augus /20 days |
| Cyclocort (amcinonide) | 0.1% cream (15 gm, 30 gm, 60 gm) | 120 grams/30 days |
| Cyclocort (amcinonide) | 0.1% lotion (60 mLs) | 120 mL/30 days |
| Cyclocort (amcinonide) | 0.1% ointment (60 gm) | 120 grams/30 days |
| Derma-Smoothe (fluocinolone acetonide) | 0.01% oil (body) (118.28 mL) | 118.28 mL/30 days |
| Derma-Smoothe (fluocinolone acetonide) | 0.01% oil (scalp) (118.28 mL) | 118.28 mL/30 days |
| Dermatop (prednicarbate) | 0.1% cream (60 gm) | 120 grams/30 days |
| Dermatop (prednicarbate) | 0.1% ointment (15 gm, 60 gm) | 120 grams/30 days |
| Desonate (desonide) | 0.05% gel (60 gm) | 120 grams/30 days |
| DesOwen (desonide) | 0.05% lotion (59 mL, 118 mL) | 118 mL/30 days |
| DesOwen, Tridesilon (desonide) | 0.05% cream (15 gm, 60 gm) | 120 grams/30 days |
| DesOwen, Tridesilon (desonide) | 0.05% circum (15 gm, 60 gm) | 120 grams/30 days |
| Betamethasone dipropionate augmented | 0.05% gel (15 gm, 50 gm) | 200 grams/28 days |
| | | |
| betamethasone dipropionate augmented | 0.05% lotion (30 mL, 60 mL) | 210 mL/30 days |
| betamethasone dipropionate augmented | 0.05% ointment (15 gm, 45 gm, 50 gm) | 200 grams/28 days |
| | 0.050/ /45 50) | 200 (20) |
| Diprolene AF (betamethasone dipropionate) | 0.05% cream (15 gm, 50 gm) | 200 grams/28 days |
| Diprosone (betamethasone dipropionate) | 0.05% cream (15 gm, 45 gm) | 135 grams/30 days |
| Diprosone (betamethasone dipropionate) | 0.05% lotion (60 mL) | 120 mL/30 days |
| betamethasone dipropionate | 0.05% ointment (15 gm, 45 gm) | 135 grams/30 days |
| mometasone furoate | 0.1% cream (15 gm, 45 gm) | 135 grams/30 days |
| Elocon (mometasone furoate) | 0.1% ointment (15 gm, 45 gm) | 135 grams/30 days |
| Elocon (mometasone furoate) | 0.1% lotion/solution (30 mL, 60 mL) | 120 mL/30 days |
| Florone (diflorasone diacetate) | 0.05% ointment (15 gm, 30 gm, 45 gm, 60 | |
| | am) | |
| Halog (halcinonide) | 0.1% cream (30 gm, 60 gm, 216 gm) | 120 grams/ 30 days |
| Halog (halcinonide) | 0.1% ointment (60 gm) | 120 grams/ 30 days |
| Halog (halcinonide) | 0.1% solution (120 mL) | 120 mL/ 30 days |
| | | |
| Hytone (hydrocortisone) | 2.5% cream (20 gm, 28 gm, 28.35 gm, 30 | 434 grains/30 days |
| Hytono (hydrocorticono) | am. 453.6 am. 454 am) | 154 grams/20 days |
| Hytone (hydrocortisone) | 1% cream (28.35 gm, 28.4 gm, 30 gm, | 454 grams/30 days |
| | 85.2 am. 453.6 am. 454 am) | 110 1/20 |
| Hytone (hydrocortisone) | 2.5% lotion (59 mL, 118 mL) | 118 mL/30 days |
| Hytone (hydrocortisone) | 1% ointment (25 gm, 28.35 gm, 28.4 gm, | 453.6 grams/30 days |
| | 110 am. 430 am. 453.6 am) | |
| Hytone (hydrocortisone) | 2.5% ointment (20 gm, 28.35 gm, 453.6 | 454 grams/30 days |
| | am. 454 am) | |
| Impeklo (clobetasol propionate) | 0.05% lotion (68 gm) | 204 grams/28 days |
| Impoyz (clobetasol propionate) | 0.025% cream (100 gm) | 200 grams/30 days |
| Kenalog (triamcinolone acetonide) | 0.147 mg/gm aerosol spray (63 gm, 100 | 126 grams/30 days |
| | am) | |
| Kenalog (triamcinolone acetonide) | 0.025% lotion (60 mL) | 120 mL/30 days |
| Kenalog (triamcinolone acetonide) | 0.1% lotion (60 mL) | 120 mL/30 days |
| Kenalog (triamcinolone acetonide) | 0.025% ointment (15 gm, 80 gm, 454 gm) | 454 grams/30 days |
| | (3 , 3 , | <i>,</i> , |
| Kenalog, Aristocort (triamcinolone acetonide) | 0.025% cream (15 gm, 80 gm, 454 gm) | 454 grams/30 days |
| Kenalog, Aristocort (triamcinolone acetonide) | 0.1% cream (15 gm, 28.4 gm, 30 gm, 80 | 454 grams/30 days |
| | am. 85.2 am. 453.6 am. 454 am) | io i giamo, co aayo |
| Kenalog, Aristocort (triamcinolone acetonide) | 0.5% cream (15 gm, 454 gm) | 454 grams/30 days |
| Kenalog, Aristocort (triamcinolone acetonide) | 0.1% ointment (15 gm, 30 gm, 80 gm, | 454 grams/30 days |
| Renaiog, Anstocore (chamemoloric acctomac) | 453.6 am. 454 am) | 434 grams, 30 days |
| Loyotto (halohotasol propionato) | | 200 grams/28 days |
| Lexette (halobetasol propionate) | 0.05% foam (50 gm, 100 gm) | 200 grams/28 days 120 mL/30 days |
| Lidex (fluocinonide) | 0.05% solution (20 mL, 60 mL) | |
| Lidex (fluocinonide) | 0.05% cream (15 gm, 30 gm, 60 gm, 120 | 120 grams/30 days |
| Liday (fluesinanida) | am) | 120 arama/20 daya |
| Lidex (fluocinonide) | 0.05% gel (15 gm, 30 gm, 60 gm) | 120 grams/30 days |
| Lidex (fluocinonide) | 0.05% ointment (15 gm, 30 gm, 60 gm) | 120 grams/30 days |
| Liday F (flygaigagida) | 0.050/ amoutable of amount (15 amount) | 120 |
| Lidex-E (fluocinonide) | 0.05% emulsified cream (15 gm, 30 gm, | 120 grams/30 days |
| | 60 am) | |
| Hydrocortisone butyrate | 0.1% solution (20 mL, 60 mL) | 120 mL/30 days |
| Hydrocortisone butyrate | 0.1% cream (15 gm, 45 gm) | 135 grams/30 days |
| Locoid (hydrocortisone butyrate) | 0.1% lotion (59 mL, 118 mL) | 118 mL/30 days |
| Locoid (hydrocortisone butyrate) | 0.1% ointment (15 gm, 45 gm) | 135 grams/30 days |
| Locoid Lipocream (hydrocortisone butyrate) | 0.1% hydrophilic lipo cream (45 gm, 60 | 120 grams/30 days |
| | am) | |
| Luxiq (betamethasone valerate) | 0.12% foam (50 gm, 100 gm) | 150 grams/30 days |
| Olux (clobetasol propionate) | 0.05% foam (50 gm, 100 gm) | 200 grams/28 days |
| Olux-E (clobetasol propionate) | 0.05% emulsion foam (50 gm, 100 gm) | 200 grams/28 days |
| Pandel (hydrocortisone probutate) | 0.1% cream (80 gm) | 160 grams/30 days |
| Diflorasone diacetate | 0.05% cream (15 gm, 30 gm, 60 gm) | 120 grams/30 days |
| Sernivo (betamethasone dipropionate) | 0.05% cream (15 gm, 50 gm, 60 gm) 0.05% spray (120 mL) | 120 mL/30 days |
| Synalar (fluocinolone acetonide) | 0.03% spray (120 mL) 0.01% solution (60 mL, 90 mL) | 120 mL/30 days |
| | 0.025% cream (15 gm, 60 gm, 120 gm) | 120 mic/30 days |
| Synalar (fluocinolone acetonide) Synalar (fluocinolone acetonide) | | |
| Synalar (fluocinolone acetonide) | 0.025% ointment (15 gm, 60 gm, 120 gm) | 120 grams/30 days |
| | | |

| - - | Synalar (fluocinolone acetonide) Temovate (clobetasol propionate) Temovate (clobetasol propionate) | 0.01% cream (15 gm, 60 gm) 0.05% solution (25 mL, 50 mL) 0.05% cream (15 gm, 30 gm, 45 gm, 60 | 120 grams/30 days 200 mL/28 days 210 grams/28 days |
|-------------------------|---|--|--|
| | Temovate (clobetasol propionate) | am) 0.05% ointment (15 gm, 30 gm, 45 gm, 60 |) 210 grams/28 days |
| | Temovate (clobetasol propionate) Temovate E (clobetasol propionate) | am) 0.05% gel (15 gm, 30 gm, 60 gm) 0.05% emollient cream (15 gm, 30 gm, 45 | 210 grams/28 days 210 grams/28 days |
| | Texacort (hydrocortisone) Topicort (desoximetasone) Topicort (desoximetasone) Topicort (desoximetasone) Topicort (desoximetasone) Topicort (desoximetasone) | am. 60 am) 2.5 % solution (30 mL) 0.05% cream (15 qm, 60 qm, 100 qm) 0.25% cream (15 qm, 60 qm, 100 qm) 0.05% gel (15 qm, 60 qm) 0.05% ointment (60 qm, 100 qm) 0.25% ointment (15 gm, 60 gm, 100 gm) | 120 mL/30 days 120 grams/30 days 120 grams/30 days 120 grams/30 days 120 grams/30 days 120 grams/30 days |
| | Topicort (desoximetasone) triamcinolone acetonide halobetasol propionate Ultravate (halobetasol propionate) halobetasol propionate Valisone (betamethasone valerate) Valisone (betamethasone valerate) betamethasone valerate Vanos (fluocinonide) Verdeso (desonide) Westcort (hydrocortisone valerate) Westcort (hydrocortisone valerate) | 0.25% spray (100 mL) 0.05% ointment (110 gm, 430 gm) 0.05% cream (15 gm, 50 gm) 0.05% lotion (60 mL, 120 mL) 0.05% ointment (15 gm, 50 gm) 0.1% cream (15 gm, 45 gm) 0.1% lotion (60 mL) 0.1% ointment (15 gm, 45 gm) 0.1% cream (30 gm, 60 gm, 120 gm) 0.05% foam (100 gm) 0.2% ointment (15 gm, 45 gm, 60 gm) 0.2% cream (15 gm, 45 gm, 60 gm) | 100 mL/30 days 430 grams/30 days 200 grams/28 days 240 mL/30 days 200 grams/28 days 135 grams/30 days 120 mL/30 days 135 grams/30 days 130 grams/30 days 140 grams/30 days 100 grams/30 days 120 grams/30 days 120 grams/30 days |
| Topical Doxepin PAQL | **Topical Doxepin QL information is included in the individual program document | | |
| Topical Lidocaine PAQL | **Topical Lidocaine QL information is included in the individual program document | | |
| Topical NSAIDs STQL | **Topical NSAID QL information is included in the individual program document | | |
| Topiramate ER PAQL | **Topiramate ER QL information is included in the individual program document | | |
| Triptan QL | **Triptan QL information is included in the individual program document | | |
| Tyrvaya PAQL | **Tyrvaya QL information is included in the individual program document | | |
| Urinary Incontinence QL | **Urinary Incontinence QL information is included in the individual program document | | |
| Vascepa PAQL | **Vascepa QL information is included in the individual program document | | |
| Verquvo PAQL | **Verguvo QL information is included in the individual program document | | |
| Vijoice PAQL | **Vijoice QL information is included in the individual program document | | |
| VMAT2 Inhibitors PAQL | **VMAT2 Inhibitors QL information is included in the individual program document | | |
| Voxzogo PAQL | **Voxzogo QL information is included in the individual program document | | |
| Vuity QL | **Vuity QL information is included in the individual program document | | |
| Weight Loss Agents PAQL | **Weight Loss Agents QL information is included in the individual program document | | |
| Xermelo PAQL | **Xermelo QL information is included in the individual program document | | |
| Xhance PAQL | **Xhance QL information is included in the individual program document | | |
| Zenosia PAOI | | | |
| Zeposia PAQL | **Zeposia QL information is included in the individual program document | | |